ALZHEIMER'S ASSOCIATION WELCOMES FDA ACTION APPROVING LEQEMBI WEEKLY SUBCUTANEOUS MAINTENANCE DOSING
(NASDAQ:BIIB) CHICAGO, Aug. 29, 2025 /PRNewswire/ -- The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early Alzheimer's disease. With this approval, Leqembi IQLIK is...
Related Questions
What impact will this new dosing regimen have on Biogen's revenue forecasts and market share compared to competing Alzheimer’s therapies such as Aduhelm and donanemab?
What are the potential risks related to insurance coverage, pricing, and supply chain that could influence the long‑term profitability of Leqembi after this approval?
How will the FDA approval of weekly subcutaneous dosing for Leqembi affect Biogen's (BIIB) stock price and trading volume in the short term?